<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005120</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangUniv</org_study_id>
    <nct_id>NCT02005120</nct_id>
  </id_info>
  <brief_title>Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC</brief_title>
  <official_title>Phase II Study of Intrapleural Administration of Bevacizumab Versus Recombinant Human Endostatin (Endostar) for Refractory Malignant Pleural Effusions in Advanced Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung
      cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial
      growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of
      pleural fluid. The other widely used treatment for MPE is recombinant human endostatin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed this clinical trial to determine the efficacy and Safety of intrapleural
      Bevacizumab versus recombinant human endostatin as a treatment for malignant pleural
      effusions (MPE) in patients with non-small cell lung cancer (NSCLC).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant human endostatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Intrapleural administration of bevacizumab</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human endostatin</intervention_name>
    <description>Intrapleural administration of recombinant human endostatin</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Endostar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient who was confirmed stage IV NSCLC with malignant pleural effusion confirmed by
        cytology.

        Males or females aged ≥18 years, &lt; 75 years. Eastern Cooperative Oncology Group (ECOG)
        performance status 0-3. Life expectancy ≥12 weeks. Ability to maintain a drainage catheter.
        Previous intrapleural administration of chemotherapeutic drugs (preferred bleomycin) Males
        and females should be contraceptive during the period of the trial until 8 weeks after the
        last administration of the drug.

        Adequate bone marrow, renal, and liver function are required. Able to comply with the
        required protocol and follow-up procedures, and able to receive oral medications.

        Institutional review board-approved informed consent will be obtained for every patient
        before initiation of any trial-specific procedure or treatment.

        Exclusion Criteria:

        Any unstable systemic disease (including active infection, uncontrolled hypertension,
        unstable angina, congestive heart failure, myocardial infarction within the previous year,
        serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).

        Active thoracic cavity or systemic bleeding. Major surgical procedure, open biopsy, or
        significant traumatic injury within 28 days prior to day 0.

        Female subjects should not be pregnant or breast-feeding. Known sensitivity to Bevacizumab
        or Endostar. Patients must not be on therapeutic anticoagulation with warfarin, heparin or
        low molecular weight heparin.

        Adequate hematological function: Absolute neutrophil count (ANC) ≥1.5 x 109/L, and Platelet
        count ≥100 x 109/L.

        Adequate renal function: Serum creatinine ≤ 1.5 x ULN, or ≥ 50 ml/min. Adequate liver
        function :Total bilirubin £ 1.5 x upper limit of normal (ULN) and Alanine Aminotransferase
        (ALT) and Aspartate Aminotransferase (AST) &lt; 2.5 x ULN in the absence of liver metastases,
        or &lt; 5 x ULN in case of liver metastases.

        Patient assessed by the investigator to be unable or unwilling to comply with the
        requirements of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiong Zhao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The first affiliated hospital, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiong Zhao, PhD</last_name>
    <phone>0571-87236802</phone>
    <email>doczq.2008@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qiong Zhao</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiong Zhao, PhD</last_name>
      <phone>0571-87236802</phone>
      <email>doczq.2008@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Qiong Zhao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiong Zhao, PhD</last_name>
      <phone>0571-87236802</phone>
      <email>doczq.2008@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Qiong Zhao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>December 19, 2013</last_update_submitted>
  <last_update_submitted_qc>December 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Qiong Zhao</investigator_full_name>
    <investigator_title>Chief of Department of Thoracic Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

